A SECRET WEAPON FOR LINSITINIB FDA APPROVAL

The LIDS demo satisfied its primary endpoint with statistical significance to the 150mg BID dose. Linsitinib Within this trial validated the protection profile viewed within the prior oncology research and importantly shown a positive protection profile on key adverse functions (AEs) of interest for the IGF-1R goal for example hearing impairment, h